**Almeida 2008** Almeida L, Falcão A, Vaz-da-Silva M, Nunes T, Santos AT, Rocha JF, Neta C, Macedo T, Fontes-Ribeiro C, Soares-da-Silva P. Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Eur J Clin Pharmacol. 2008 Oct;64(10):961-6. doi: 10.1007/s00228-008-0534-2.

**Avdeef 1998** Avdeef A, Box KJ, Comer JE, Hibbert C, Tam KY. pH-metric logP 10. Determination of liposomal membrane-water partition coefficients of ionizable drugs. Pharm Res. 1998 Feb;15(2):209-15. doi: 10.1023/a:1011954332221. 

**Bi 2018** Bi YA, Lin J, Mathialagan S, Tylaska L, Callegari E, Rodrigues AD, Varma MVS. Role of Hepatic Organic Anion Transporter 2 in the Pharmacokinetics of R- and S-Warfarin: In Vitro Studies and Mechanistic Evaluation. Mol Pharm. 2018 Mar 5;15(3):1284-1295. doi: 10.1021/acs.molpharmaceut.7b01108. 

**Crewe 2011** Crewe HK, Barter ZE, Yeo KR, Rostami-Hodjegan A. Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factors. Biopharm Drug Dispos. 2011 Sep;32(6):303-18. doi: 10.1002/bdd.760. 

**Dingemanse 2013** Dingemanse J, Hoever P. Absence of pharmacokinetic and pharmacodynamic interactions between almorexant and warfarin in healthy subjects. Drugs R D. 2013 Jun;13(2):145-51. doi: 10.1007/s40268-013-0017-5. 

**Drugbank** DrugBank DB00682 https://go.drugbank.com/drugs/DB00682, accessed 26-08-2025.

**Essential Health** https://essentiahealth.testcatalog.org/show/LABFWARP#:~:text=The%20blood%20to%20plasma,ratio%20is%20approximately%200.5., accessed 14-10-2025.

**FDA 2010** COUMADIN® TABLETS, FDA drug label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/009218s108lbl.pdf

**Frymoyer 2010** Frymoyer A, Shugarts S, Browne M, Wu AH, Frassetto L, Benet LZ. Effect of single-dose rifampin on the pharmacokinetics of warfarin in healthy volunteers. Clin Pharmacol Ther. 2010 Oct;88(4):540-7. doi: 10.1038/clpt.2010.142. Epub 2010 Aug 11. 

**Dickinson 2007** Dickinson GL, Lennard MS, Tucker GT, Rostami-Hodjegan A. The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example. Br J Clin Pharmacol. 2007 Jul;64(1):14-26. doi: 10.1111/j.1365-2125.2007.02850.x. Epub 2007 Feb 12.

**Jones 2010**Jones DR, Kim SY, Boysen G, Yun CH, Miller GP. Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin. Drug Metab Lett. 2010 Dec;4(4):213-9. doi: 10.2174/187231210792928242.

**Lilja 2007** Lilja JJ, Backman JT, Neuvonen PJ. Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam--probes of CYP2C9, CYP1A2, and CYP3A4. Clin Pharmacol Ther. 2007 Jun;81(6):833-9. doi: 10.1038/sj.clpt.6100149. Epub 2007 Mar 28. 

**Geng 2024** Geng K, Shen C, Wang X, Wang X, Shao W, Wang W, Chen T, Sun H, Xie H. A physiologically-based pharmacokinetic/pharmacodynamic modeling approach for drug-drug-gene interaction evaluation of S-warfarin with fluconazole. CPT Pharmacometrics Syst Pharmacol. 2024 May;13(5):853-869. doi: 10.1002/psp4.13123. 

**He 2007** He YL, Sabo R, Riviere GJ, Sunkara G, Leon S, Ligueros-Saylan M, Rosenberg M, Dole WP, Howard D. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Curr Med Res Opin. 2007 May;23(5):1131-8. doi: 10.1185/030079907x188008.

**Kim 2001** Kim JS, Nafziger AN, Gaedigk A, Dickmann LJ, Rettie AE, Bertino JS Jr. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe. J Clin Pharmacol. 2001 Jul;41(7):715-22. doi: 10.1177/00912700122010618.

**Kim 2019** Kim YJ, Jeong JW, Song Y, Koo TS. Effects of formulation types on pharmacodynamics of warfarin in patients with cerebral infarction and dysphagia. Clin Pharmacol. 2019 Mar 13;11:51-56. doi: 10.2147/CPAA.S184232. 

**Liao 1996** Liao S, Palmer M, Fowler C, Nayak RK. Absence of an effect of levofloxacin on warfarin pharmacokinetics and anticoagulation in male volunteers. J Clin Pharmacol. 1996 Nov;36(11):1072-7. doi: 10.1177/009127009603601111. 

**Macha 2013** Macha S, Rose P, Mattheus M, Pinnetti S, Woerle HJ. Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers. Diabetes Obes Metab. 2013 Apr;15(4):316-23. doi: 10.1111/dom.12028. Epub 2012 Nov 22.

**Maddison 2013** Maddison J, Somogyi AA, Jensen BP, James HM, Gentgall M, Rolan PE. The pharmacokinetics and pharmacodynamics of single dose (R)- and (S)-warfarin administered separately and together: relationship to VKORC1 genotype. Br J Clin Pharmacol. 2013 Jan;75(1):208-16. doi: 10.1111/j.1365-2125.2012.04335.x. 

**Malhotra 2011** Malhotra B, Alvey C, Gong J, Li X, Duczynski G, Gandelman K. Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. Br J Clin Pharmacol. 2011 Aug;72(2):257-62. doi: 10.1111/j.1365-2125.2011.03989.x. 

**Mallikaarjun 1999** Mallikaarjun S, Bramer SL. Effect of cilostazol on the pharmacokinetics and pharmacodynamics of warfarin. Clin Pharmacokinet. 1999;37 Suppl 2:79-86. doi: 10.2165/00003088-199937002-00009. 

**Ngo 2010** Ngo N, Brantley SJ, Carrizosa DR, Kashuba AD, Dees EC, Kroll DJ, Oberlies NH, Paine MF. The warfarin-cranberry juice interaction revisited: A systematic in vitro-in vivo evaluation. J Exp Pharmacol. 2010 Jul;2010(2):83-91. doi: 10.2147/JEP.S11719. 

**O'Sullivan 1993** O'Sullivan TA, Wang JP, Unadkat JD, al-Habet SM, Trager WF, Smith AL, McNamara S, Aitken ML. Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. Clin Pharmacol Ther. 1993 Sep;54(3):323-8. doi: 10.1038/clpt.1993.154. 

**Ouellet 2006** Ouellet D, Bramson C, Carvajal-Gonzalez S, Roman D, Randinitis E, Remmers A, Gardner MJ. Effects of lasofoxifene on the pharmacokinetics and pharmacodynamics of single-dose warfarin. Br J Clin Pharmacol. 2006 Jun;61(6):741-5. doi: 10.1111/j.1365-2125.2006.02589.x. 

**Rahimy 2002** Rahimy M, Hallén B, Narang P. Effect of tolterodine on the anticoagulant actions and pharmacokinetics of single-dose warfarin in healthy volunteers. Arzneimittelforschung. 2002;52(12):890-5. doi: 10.1055/s-0031-1299986.

**Rettie 1992** Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, Trager WF. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol. 1992 Jan-Feb;5(1):54-9. doi: 10.1021/tx00025a009.

**Sanwald Ducray 2014** Sanwald-Ducray P, Jamois C, Banken L. The effect of aleglitazar on the pharmacokinetics and pharmacodynamics of S- and R-warfarin in healthy male subjects. J Cardiovasc Pharmacol. 2014 Feb;63(2):152-7. doi: 10.1097/FJC.0000000000000033.

**Sawada 1985** Sawada Y, Hanano M, Sugiyama Y, Iga T. Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats. J Pharmacokinet Biopharm. 1985 Oct;13(5):477-92. doi: 10.1007/BF01059331.

**Shaik 2016** Shaik AN, Grater R, Lulla M, Williams DA, Gan LL, Bohnert T, LeDuc BW. Comparison of enzyme kinetics of warfarin analyzed by LC-MS/MS QTrap and differential mobility spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Jan 1;1008:164-173. doi: 10.1016/j.jchromb.2015.11.036. Epub 2015 Nov 23.

**Schwartz 2008** Schwartz JI, Dunbar S, Yuan J, Li S, Gipson A, Rosko K, Johnson-Levonas AO, Lasseter KC, Addy C, Stoch AS, Wagner JA. Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin. Adv Ther. 2008 Nov;25(11):1175-90. doi: 10.1007/s12325-008-0116-9. 

**Sidharta 2014** Sidharta PN, Dietrich H, Dingemanse J. Investigation of the effect of macitentan on the pharmacokinetics and pharmacodynamics of warfarin in healthy male subjects. Clin Drug Investig. 2014 Aug;34(8):545-52. doi: 10.1007/s40261-014-0207-0.

**Soon 2006** Soon D, Kothare PA, Linnebjerg H, Park S, Yuen E, Mace KF, Wise SD. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. J Clin Pharmacol. 2006 Oct;46(10):1179-87. doi: 10.1177/0091270006291622. 

**Stella 1984** Stella VJ, Mooney KG, Pipkin JD. Dissolution and ionization of warfarin. J Pharm Sci. 1984 Jul;73(7):946-8. doi: 10.1002/jps.2600730721. 

**Stockis 2013** Stockis A, van Lier JJ, Cawello W, Kumke T, Eckhardt K. Lack of effect of lacosamide on the pharmacokinetic and pharmacodynamic profiles of warfarin. Epilepsia. 2013 Jul;54(7):1161-6. doi: 10.1111/epi.12192. 

**Takahashi 2003** Takahashi H, Wilkinson GR, Caraco Y, Muszkat M, Kim RB, Kashima T, Kimura S, Echizen H. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther. 2003 Mar;73(3):253-63. doi: 10.1067/mcp.2003.26a.

**Toon 1987** Toon S, Hopkins KJ, Garstang FM, Rowland M. Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man. Eur J Clin Pharmacol. 1987;32(2):165-72. doi: 10.1007/BF00542190. 

**Toon 1990** Toon S, Holt BL, Mullins FG, Bullingham R, Aarons L, Rowland M. Investigations into the potential effects of multiple dose ketorolac on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol. 1990 Nov;30(5):743-50. doi: 10.1111/j.1365-2125.1990.tb03845.x. 

**Turpeinen 2013** Turpeinen M, Uusitalo J, Lehtinen T, Kailajärvi M, Pelkonen O, Vuorinen J, Tapanainen P, Stjernschantz C, Lammintausta R, Scheinin M. Effects of ospemifene on drug metabolism mediated by cytochrome P450 enzymes in humans in vitro and in vivo. Int J Mol Sci. 2013 Jul 5;14(7):14064-75. doi: 10.3390/ijms140714064. 

**Uygungül 2014** Uygungül E, Ayrik C, Narci H, Erdoğan S, Toker I, Demir F, Karaaslan U. Determining risk factors of bleeding in patients on warfarin treatment. Adv Hematol. 2014;2014:369084. doi: 10.1155/2014/369084. 

**Weber 1999** Weber C, Banken L, Birnboeck H, Schulz R. Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol. 1999 Aug;39(8):847-54. doi: 10.1177/00912709922008380. 

**Wittkowsky 2003** Wittkowsky AK. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med. 2003 Aug;3(3):221-30. doi: 10.1055/s-2003-44457.

**Yin 2011** Yin OQ, Gallagher N, Fischer D, Zhao L, Zhou W, Leroy E, Golor G, Schran H. Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects. Clin Drug Investig. 2011;31(3):169-79. doi: 10.2165/11538700-000000000-00000. 

**Yong 2009** Yong WP, Kim TW, Undevia SD, Innocenti F, Ratain MJ. R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9. Eur J Cancer. 2009 Jul;45(11):1904-8. doi: 0.1016/j.ejca.2009.04.032. 

